Active, not recruitingPhase 2NCT05177211
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
Studying Chronic neutrophilic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Principal Investigator
- Andrew Kuykendall, MDMoffitt Cancer Center
- Intervention
- Fedratinib Pill(drug)
- Enrollment
- 25 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (3)
- Moffitt Cancer Center, Tampa, Florida, United States
- University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
- Cleveland Clinic, Cleveland, Ohio, United States
Collaborators
Bristol-Myers Squibb
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05177211 on ClinicalTrials.gov